Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bryostatin-1 for HIV-1 Latency
NCT02269605Phase 1Completed
- Start
- Sep 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bryostatin-1 in human immunodeficiency virus infection (HIV) (3 arms). Primary endpoint: Intracellular HIV-1 RNA (usRNA and msRNA) level at Day 3. Started Sep 2014; status: completed.
02
Drugs
bryostatin-1
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02269605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269605.